Morgan Stanley
NSRX

Morgan Stanley’s Nasus Pharma NSRX Stock Holding History

Morgan Stanley’s Portfolio NSRX Stock Details NSRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.5K Sell
1,000
-1,000
-50% -$2.93K ﹤0.01% 7298
2026
Q1 		$4.44K Hold
2,000
– – ﹤0.01% 7170
2025
Q4 		$18.3K Hold
2,000
– – ﹤0.01% 6718
2025
Q3 		$13.3K Buy
+2,000
New +$16.1K ﹤0.01% 6817

Other funds holding NSRX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Morgan Stanley's NSRX Position: Q2 2026 in Review

Morgan Stanley reduced its Nasus Pharma (NSRX) stake by 50% in Q2 2026, selling an estimated $2.93K and leaving 1,000 shares worth $3.5K. The position accounts for ﹤0.01% of the portfolio, ranked #7298.

Morgan Stanley first reported a position in NSRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $18.3K in Q4 2025. 10 funds tracked by Wall St. Rank hold NSRX as of Q2 2026.

  • Morgan Stanley held 1,000 shares of Nasus Pharma worth $3.5K as of Q2 2026.
  • Morgan Stanley sold 1,000 Nasus Pharma shares in Q2 2026, an estimated $2.93K.
  • Nasus Pharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7298 holding.
  • Morgan Stanley first reported a position in Nasus Pharma in Q3 2025 and has held it in 4 quarters since.
  • Morgan Stanley's Nasus Pharma position peaked at $18.3K in Q4 2025.
  • 10 funds tracked by Wall St. Rank held Nasus Pharma as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.